LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

LLY

1,040.03

+0.29%↑

JNJ

243.3

-0.53%↓

ABBV

231.41

+1.75%↑

NVS

162.81

+1.21%↑

MRK

121.33

+1.83%↑

Home・Akcijų sąrašas・Erasca Inc

Erasca Inc

Uždarymo kaina

11.99 -1.56

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

11.88

Max

12.64

Pagrindiniai rodikliai
By Trading Economics
Pajamos	3.3M -31M
Darbuotojai	103
EBITDA	8.3M -30M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	-9.41% downside

Dividendai
By Dow Jones
Kitas uždarbis	2026-03-18

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	3.1B 3.7B
Ankstesnė atidarymo kaina	13.55
Ankstesnė uždarymo kaina	11.99

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Bearish Evidence

1.39 / 1.44 Palaikymas ir pasipriešinimas

Erasca Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-02-13 16:32; UTC

Uždarbis

Enbridge, TC Energy Investing in Opportunities to Tap Rising Energy Demand, Boom in Data Centers -- Update

2026-02-13 21:57; UTC

Uždarbis

Stocks Rise on Softer Inflation Data, but AI Jitters Trigger Worst Week Since November -- WSJ

2026-02-13 21:50; UTC

Rinkos pokalbiai

Basic Materials Roundup: Market Talk

2026-02-13 21:20; UTC

Uždarbis

Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More Stock Market Movers -- Barrons.com

2026-02-13 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Constellation Software: Lumine Group Completes Acquisition of Synchronoss Technologies >CSU.T SNCR

2026-02-13 20:45; UTC

Rinkos pokalbiai

Global Forex and Fixed Income Roundup: Market Talk

2026-02-13 20:45; UTC

Rinkos pokalbiai

Dollar Pares Down Early Losses -- Market Talk

2026-02-13 20:39; UTC

Rinkos pokalbiai

Potential for Mild Winter Ahead Sinks Natural Gas for Week -- Market Talk

2026-02-13 20:28; UTC

Rinkos pokalbiai

Oil Settles Week Lower -- Market Talk

2026-02-13 19:51; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026-02-13 19:32; UTC

Rinkos pokalbiai

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026-02-13 19:32; UTC

Rinkos pokalbiai

Gold and Silver Climb to Finish Week In Positive Territory -- Market Talk

2026-02-13 19:29; UTC

Uždarbis

Big Tech's Spending Spree Could Limit Buybacks and Dividends -- Barrons.com

2026-02-13 18:18; UTC

Įsigijimai, susijungimai, perėmimai

Exxon, Walmart and 9 Other Stocks That Are Soaring Because Cash Is King Again -- Barrons.com

2026-02-13 17:52; UTC

Uždarbis

Pinterest's Earnings Give More Proof of Meta Platform's Dominance -- Barrons.com

2026-02-13 17:16; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Arista, Fastly, Coinbase, Robinhood, DraftKings, and More -- Barrons.com

2026-02-13 17:10; UTC

Įsigijimai, susijungimai, perėmimai

Vibe-Coding in Gas Town? A Guide to the Software Selloff With 4 Sexy Stock Picks. -- Barrons.com

2026-02-13 16:59; UTC

Uždarbis

AppLovin Stock Stabilizes After Selloff. Its Biggest Critic Waves the White Flag. -- Barrons.com

2026-02-13 16:39; UTC

Įsigijimai, susijungimai, perėmimai

Berkshire Might Have Sold More Apple, Bank of America Stock in Fourth Quarter -- Barrons.com

2026-02-13 16:11; UTC

Uždarbis

Nvidia Stock Wobbles. The Focus Is Turning to Earnings. -- Barrons.com

2026-02-13 16:07; UTC

Rinkos pokalbiai

Hungarian Forint Could Rise Further -- Market Talk

2026-02-13 15:54; UTC

Uždarbis

Detroit Automakers Take $50 Billion Hit as EV Bubble Bursts -- WSJ

2026-02-13 15:26; UTC

Rinkos pokalbiai

Indian Imports of Saudi Crude Hit Highest Since 2022 -- Market Talk

2026-02-13 15:01; UTC

Uždarbis

These Stocks Are Today's Movers: Applied Materials, Rivian, Moderna, Steel Dynamics, Coinbase, DraftKings, Tri Pointe Homes, and More -- Barrons.com

2026-02-13 15:00; UTC

Uždarbis

Expedia Falls, but Airbnb Rises. Why Online Travel Stocks Face a Tough Year. -- Barrons.com

2026-02-13 14:50; UTC

Rinkos pokalbiai

Oil Moves Lower As Market Weighs Geopolitical Risk -- Market Talk

2026-02-13 14:44; UTC

Uždarbis

Arista Networks Stock Climbs. Why It Is Outshining Cisco. -- Barrons.com

2026-02-13 14:22; UTC

Rinkos pokalbiai

Uždarbis

Global Energy Roundup: Market Talk

2026-02-13 14:21; UTC

Rinkos pokalbiai

Uždarbis

TC Energy's Broadly Anticipated Results Expected To Have Neutral Response -- Market Talk

2026-02-13 14:13; UTC

Rinkos pokalbiai

U.S. Natural Gas Futures Move Lower -- Market Talk

Akcijų palyginimas

Kainos pokytis

Erasca Inc Prognozė

Kainos tikslas

By TipRanks

-9.41% į apačią

12 mėnesių prognozė

Vidutinis 10.88 USD -9.41%

Aukščiausias 16 USD

Žemiausias 2 USD

Remiantis 8 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Erasca Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

8 ratings

Pirkti

Laikyti

Parduoti

Remiantis 8 analitikų, pateikusių Erasca Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.39 / 1.44Palaikymas ir pasipriešinimas

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Erasca Inc

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.